title: Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth.
abstract: BACKGROUND
  Despite the widespread use of antenatal corticosteroids to prevent respiratory distress syndrome in preterm infants, there is currently no consensus as to the type of corticosteroid to use; nor the dose, frequency, timing of use or the route of administration.
  
  
  OBJECTIVE
  To assess the effects of different corticosteroid regimens for women at risk of preterm birth.
  
  
  METHODS
  We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (13 February 2013).
  
  
  METHODS
  All identified published and unpublished randomised controlled trials or quasi-randomised control trials comparing any two corticosteroids (dexamethasone or betamethasone or any other corticosteroid that can cross the placenta), comparing different dose regimens (including frequency and timing of administration) in women at risk of preterm birth were included. We planned to exclude cross-over trials and cluster-randomised trials. We included studies published as abstracts only along with studies published as full-text manuscripts
  
  
  METHODS
  Two review authors independently assessed study eligibility, extracted data and assessed the risk of bias of included studies. Data were checked for accuracy.
  
  
  RESULTS
  For this update, 12 trials (1557 women and 1661 infants) were included. Dexamethasone was associated with a reduced risk of intraventricular haemorrhage (IVH) compared with betamethasone (risk ratio (RR) 0.44, 95% confidence interval (CI) 0.21 to 0.92; four trials, 549 infants). No statistically significant differences were seen for other primary outcomes: respiratory distress syndrome (RDS) (RR 1.06, 95% CI 0.88 to 1.27; five trials, 753 infants) and perinatal death (neonatal death RR 1.41, 95% CI 0.54 to 3.67; four trials, 596 infants). Similarly, very few differences were seen for secondary outcomes such as rate of admission to the neonatal intensive care unit (NICU) although in one trial, those infants exposed to dexamethasone, compared with betamethasone, had a significantly shorter length of NICU admission (mean difference (MD) -0.91 days, 95% CI -1.77 to -0.05; 70 infants). Results for biophysical parameters were inconsistent, but mostly no clinically important differences were seen.Compared with intramuscular dexamethasone, oral dexamethasone significantly increased the incidence of neonatal sepsis (RR 8.48, 95% CI 1.11 to 64.93) in one trial of 183 infants. No statistically significant differences were seen for other outcomes reported.Apart from a reduced maternal postpartum length of stay for women who received betamethasone at 12-hourly intervals compared to 24-hourly intervals in one trial (MD -0.73 days, 95% CI -1.28 to -0.18; 215 women), no differences in maternal or neonatal outcomes were seen between the different betamethasone dosing intervals assessed. Similarly, no significant differences in outcomes were seen when betamethasone acetate and phosphate was compared with betamethasone phosphate in one trial.
  
  
  CONCLUSIONS
  It remains unclear whether one corticosteroid (or one particular regimen) has advantages over another.Dexamethasone may have some benefits compared with betamethasone such as less IVH, and a shorter length of stay in the NICU. The intramuscular route may have advantages over the oral route for dexamethasone, as identified in one small trial. Apart from the suggestion that 12-hour dosing may be as effective as 24-hour dosing of betamethasone based on one small trial, few other conclusions about optimal antenatal corticosteroid regimens were able to be made. No long-term results were available except for a small subgroup of 18 month old children in one trial. Trials comparing the commonly used corticosteroids are most urgently needed, as are trials of dosages and other variations in treatment regimens.
authors.affiliation: Mercy Hospital for Women, Heidelberg, Australia.
authors.forename: Fiona C
authors.initials: FC
authors.lastname: Brownfoot
authors.forename: Daniela I
authors.initials: DI
authors.lastname: Gagliardi
authors.forename: Emily
authors.initials: E
authors.lastname: Bain
authors.forename: Philippa
authors.initials: P
authors.lastname: Middleton
authors.forename: Caroline A
authors.initials: CA
authors.lastname: Crowther
mesh_terms: D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D001507:Beclomethasone / Q000008:administration & dosage; D002543:Cerebral Hemorrhage / Q000517:prevention & control; D002552:Cerebral Ventricles; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D005325:Fetal Organ Maturity / Q000187:drug effects*; D006801:Humans; D007273:Injections, Intramuscular; D008168:Lung / Q000187:drug effects / Q000196:embryology*; D011247:Pregnancy; D047928:Premature Birth
chemical_list: D000305:Adrenal Cortex Hormones; D003907:Dexamethasone; D001507:Beclomethasone